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Abstract
During pilot studies to investigate the presence of viral RNA of xenotropic murine leukemia virus (MLV)-related
virus (XMRV) infection in sera from chronic fatigue syndrome (CFS) patients in Japan, a positive band was
frequently detected at the expected product size in negative control samples when detecting a partial gag region
of XMRV using a one-step RT-PCR kit. We suspected that the kit itself might have been contaminated with small
traces of endogenous MLV genome or XMRV and attempted to evaluate the quality of the kit in two independent
laboratories. We purchased four one-step RT-PCR kits from Invitrogen, TaKaRa, Promega and QIAGEN in Japan. To
amplify the partial gag gene of XMRV or other MLV-related viruses, primer sets (419F and 1154R, and GAG-I-F and
GAG-I-R) which have been widely used in XMRV studies were employed. The nucleotide sequences of the
amplicons were determined and compared with deposited sequences of a polytropic endogenous MLV (PmERV),
XMRV and endogenous MLV-related viruses derived from CFS patients. We found that the enzyme mixtures of the
one-step RT-PCR kit from Invitrogen were contaminated with RNA derived from PmERV. The nucleotide sequence
of a partial gag region of the contaminant amplified by RT-PCR was nearly identical (99.4% identity) to a PmERV on
chromosome 7 and highly similar (96.9 to 97.6%) to recently identified MLV-like viruses derived from CFS patients.
We also determined the nucleotide sequence of a partial env region of the contaminant and found that it was
almost identical (99.6%) to the PmERV. In the investigation of XMRV infection in patients of CFS and prostate
cancer, researchers should prudently evaluate the test kits for the presence of endogenous MLV as well as XMRV
genomes prior to PCR and RT-PCR tests.
Findings
Xenotropic murine leukemia virus (MLV)-related virus
(XMRV), which resembles endogenous MLV, was dis-
covered in prostate cancer patients in 2006 [1,2]. In
2009, a high incidence of XMRV infection was also
documented in chronic fatigue syndrome (CFS) patients
in the United States [3]. Since then, surveys on XMRV
infection of CFS patients have been conducted in sev-
eral countries [4-9]; however, there is a vigorous debate
over conflicting results in CFS patients [10-12]. More-
over, recently, Lo et al. detected MLV-related viruses
which are distinct from XMRV but resemble polytropic
endogenous MLVs in CFS patients and healthy blood
donors [13].
In studies investigating XMRV infection, a PCR
approach to detect proviral DNA and/or a RT-PCR
approach to detect viral RNA have been commonly
employed [1,3-6,8,13-15]. We (the Japanese Red Cross
[JRC]) have been studying the prevalence of XMRV
infection in Japanese patients with prostate cancer and
CFS as well as healthy blood donors. To study the pre-
sence of XMRV RNA in plasma from CFS patients, we
selected a commercial one-step RT-PCR kit. In the pilot
study, we encountered a puzzling result. A positive band
was frequently detected at the expected product size in
the negative control (water) using primer sets to detect
a partial gag region of XMRV. We suspected that the
test kit itself might have been contaminated with small
traces of endogenous MLV genome or XMRV and
attempted to evaluate the quality of the kit in two inde-
pendent laboratories, in JRC and Institute for Virus
Research (IVR), Kyoto University (Kyoto, Japan).
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any medium, provided the original work is properly cited.We used the following RT-PCR kits which were pur-
chased in Japan: SuperScript
®III One-Step RT-PCR
System with the Platinum
® Taq High Fidelity Kit (Cat.
no. 12574-030) (Invitrogen, Carlsbad, CA, USA)
(abbreviated as Kit I); AccessQuick™RT-PCR Sysytem
(Cat. no. A1701) (Promega, Madison, WI, USA)
(abbreviated as Kit P); One Step RT-PCR Kit (Cat. no.
P R O 2 4 A )( T a K a R a ,O h t s u ,S h i g a ,J a p a n )( A b b r e v i a t e d
as Kit T); One Step RT-PCR Kit (Cat. no. 210210)
(QIAGEN GmbH, Hilden, Germany) (Abbreviated as
Kit Q).
To amplify the partial gag gene of XMRV or other
MLV-related viruses, primers 419F (5’-ATCAGTT
AACCTACCCGAGTCGGAC-3’) and 1154R (5’-GCC
GCCTCTTCTTCATTGTTCTC-3’) [3], and GAG-I-F
(5’-TCTCGAGATCATGGGACAGA-3’)a n dG A G - I - R
(5’-AGAGGGTAAGGGCAGGGTAA-3’)[ 1 ]w e r eu s e d .
To amplify the partial env gene of polytropic endogenous
MLV, primers p-env1f (5’-AGAAGGTCCAGCGTTCT-
CAA-3’), p-env1r (5’-TTGCCACAGTAGCCCTCTCT-
3’), p-env3f (5’-GATGAGACTGGACTCGGGTG-3’)a n d
p-env5r (5’-GTGGAGGCCTGGGGAGCATGATC-3’)
were designed based on the sequence of a polytropic
endogenous MLV (PmERV) present in mouse (Mus mus-
culus) chromosome (chr) 7 [GenBank: AC167978]. To
enhance one-step RT-PCR reactions, 2.5 μlo f1μg/μl
carrier RNA from QIAamp UltraSens™ Virus Kit (Cat.
no. 53704) (QIAGEN) was added to the reaction mix-
tures of the one-step RT-PCR reactions as indicated in
Figure 1. To examine whether the contaminant was
RNA, 2 μlo f1 0μg/ml RNaseA (Cat. no. 19101) (QIA-
GEN) were added in the one-step RT-PCR reaction mix-
ture as indicated in Figure 1C. The RT-PCR was
conducted in 25 μl (Kit I, Kit T, and Kit Q) or 25.5 μl
(Kit P) of reaction mixture according to manufacturers’
instructions.
By adding carrier RNA in the samples to enhance the
RT-PCR reaction, we consistently detected a positive
band using Kit I in negative controls using two primer
sets (419F and 1154R, and GAG-I-F and GAG-I-R)
which are widely used to amplify XMRV (Figure 1A).
These results were confirmed by two independent
laboratories (JRC and IVR) under the same experimental
conditions. The positive reaction was observed in all
four batches (derived from four different lots) of the kit
tested. To exclude the possibility that water, the carrier
RNA or the primers used were contaminated with an
XMRV-like genome, we tested additional one-step RT-
PCR kits, termed Kit P and Kit T, from two different
manufacturers. Consequently, we could not detect posi-
tive bands utilizing these kits (Figure 1B) strongly sug-
gesting that the component(s) of Kit I contained
XMRV-like viral genomes. Most of the contaminants
appeared to be RNA because the positive bands
disappeared after adding RNaseA in the reaction mix-
ture from Kit I (Figure 1C).
To further investigate the contaminant in Kit I,
nucleic acids purified from the enzymes (a mixture of
reverse transcriptase and Taq DNA polymerase) and the
buffer contained in the kit were tested by adding the
individual components to three different one-step RT-
PCR kits (Kit T, Kit P, and Kit Q) (Figure 2A-C). As a
result, we detected positive bands when the nucleic
acids purified from the enzymes of Kit I were added to
RT-PCR Kit T, Kit P or Kit Q using two primer sets
(419F and 1154R, and GAG-I-F and GAG-I-R). On the
contrary, we could not detect the presence of MLV gen-
omes in the buffer of Kit I. These data indicated that
the enzyme mixture of Kit I was contaminated with
XMRV-like viral RNA.
PCR products amplified using primers 419F and
1154R were cloned into pCR4Blunt -TOPO (Invitro-
gen) and sequenced for both strands. Three clones
( t w oc l o n e sa tJ R Ca n do n ec l o n ea tI V R )w e r e
sequenced and found to be nearly identical (one
nucleotide difference between one another). These
sequences have a 9 nucleotide deletion observed in
some endogenous polytropic MLVs in place of the
XMRV-specific 24 nucleotide deletion in the 5’ gag lea-
der region and are nearly identical to polytropic endo-
genous MLVs encoded in multiple chromosomal
locations of the C57BL/6J mouse genome. The nucleo-
tide sequences of the representative clone [GenBank:
AB597300] were aligned with sequences deposited in
GenBank as follows: MLV-like virus from CFS patients
types 1, 2 and 3 [GenBank: HM630562, HM630558,
and HM630559] [13], XMRV strain VP62 [GenBank:
NC_007815] [2] and one representative PmERV on chr
7 [GenBank: AC167978; nt 65,391-64,647] (Figure 3).
The contaminant was nearly identical (99.4% identity)
to the PmERV chr 7 with only 4 nucleotide differences
in the sequenced region. In addition, the contaminant
was quite similar (96.9-97.6% identity) to the MLV-like
viral sequences (CFS types 1, 2, and 3) derived from
CFS patients.
To further characterize the contaminant, we con-
ducted additional RT-PCRs (Figure 1D) amplifying par-
tial env regions with two primer sets (p-env1f and
p-env1r, and p-env3f and p-env5r) based on the
sequence of the PmERV chr 7, and then sequenced the
amplicons directly. We determined 674 bp of the N-
terminal env region [GenBank: AB597301] and found
that the contaminant was nearly identical (99.6% iden-
tity) to the PmERV chr 7 [GenBank: AC167978; nt
59,992-59,319] (Figure 4).
It should be noted that Kit I contains an anti-DNA
polymerase monoclonal antibody to accomplish hot
start-PCR and to reduce non-specific amplification.
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Page 2 of 7Mice have enormous copy numbers of endogenous ret-
roviruses in their genomes; and hybridomas, for manu-
facturing monoclonal antibodies, have been found to
produce high amounts of retroviral particles [16]. There-
fore, we suspect that the Taq DNA polymerase in Kit I
was contaminated with the endogenous MLVs. This
possibility has been also pointed out by others [17,18].
Because the reverse transcriptase (SuperScriptIII) and
the Taq DNA polymerase (Platinum Taq) in Kit I can
be purchased separately from the manufacturer, we
attempted to detect the MLV genome in the Platinum
Taq polymerase using the same protocol as the one per-
formed in Figure 2A-B. As a result, we detected MLV
genomes in the Platinum Taq DNA polymerase using
the RT-PCR Kit P and Kit T (Figure 2D for Kit P and
data not shown for Kit T).
Surveys have been conducted by several research
groups on XMRV infection in CFS patients, but the
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Figure 1 Amplification of MLV-like viral sequences in Kit I. (A) One-step RT-PCR was conducted using Kit I with the indicated primer sets.
The RT-PCR conditions were as follows: reverse transcription at 55°C for 30 minutes; activation at 94°C for 2 minutes; 35 (lanes 1, 3, 5 and 7) or
45 cycles (lanes 2, 4, 6 and 8) of the following steps: 94°C for 15 s, 57°C for 30 s, and 68°C for 1 minute; and a final extension at 68°C for 3
minutes. Lanes 1, 2, 5 and 6: one-step RT-PCR with carrier RNA; Lanes 3, 4, 7 and 8: one-step RT-PCR without carrier RNA. Each reaction was
carried out in duplicate. (B) One-step RT-PCR was conducted using Kit T (left panel) and Kit P (right panel) with primers 419F and 1154R with or
without carrier RNA. The RT-PCR conditions using Kit T were as follows: reverse transcription at 50°C for 30 minutes; activation at 94°C for 2
minutes; 45 cycles of the following steps: 94°C for 30 s, 57°C for 30 s, and 72°C for 1 minute; and a final extension at 72°C for 10 minutes. The
RT-PCR conditions using Kit P were as follows: reverse transcription at 45°C for 45 minutes; activation at 95°C for 2 minutes; 45 cycles of the
following steps: 95°C for 30 s, 57°C for 30 s, and 70°C for 45 s; and a final extension at 70°C for 5 minutes. (C) One-step RT-PCR was conducted
with primers GAG-I-F and GAG-I-R using Kit I with or without RNaseA. Carrier RNA was not added to the reaction mixtures. The RT-PCR
conditions were as follows: reverse transcription at 55°C for 30 minutes; activation at 94°C for 2 minutes; 45 cycles of the following steps: 94°C
for 15 s, 57°C for 30 s, and 68°C for 1 minute; and a final extension at 68°C for 3 minutes. (D) One-step RT-PCR was conducted using Kit I to
amplify env region of the contaminants. One-step RT-PCR was carried out using two primer sets p-env1f and p-env1r (lane 1), and p-env3f and
p-env5r (lane 2). The RT-PCR conditions were the same as in Figure 1C with the exception of the number of PCR cycles (60 cycles instead of 45
cycles). M: DNA size marker.
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Figure 2 One-step RT-PCR for identification of contaminants in Kit I and Platinum Taq. (A-C) One-step RT-PCR for identification of a
contaminated component in Kit I. The experiments were conducted in two independent laboratories, IVR and JRC. In IVR, nucleic acids were
extracted from 50 μl of the enzyme mix of the RT-PCR Kit I using an RNA purification column (QIAamp viral RNA mini kit [Cat. no. 52904]
[QIAGEN]) and the presence of polytropic endogenous MLV was examined by using the RT-PCR Kit T (A) and Kit P (B). In JRC, nucleic acids were
extracted from 75 μl of the enzyme mix of RT-PCR Kit I using an RNA/DNA purification column (PureLink™ Viral RNA/DNA Kit [Cat. no. 12280-050]
[Invitrogen]), and the presence of polytropic endogenous MLV was examined using Kit Q (C). Five μl of test samples were examined with
primers indicated below the corresponding lanes. The RT-PCR conditions for Kit T and Kit P were the same as in Figure 1B. The RT-PCR
conditions for Kit Q were as follows: reverse transcription at 50°C for 30 minutes; activation at 95°C for 15 minutes; 45 cycles of the following
steps: 94°C for 30 s, 57°C for 30 s, and 72°C for 1 minute; and a final extension at 72°C for 10 minutes. Lanes 1 and 5, DW; lanes 2 and 6,
column-purified carrier RNA (carrier); lanes 3 and 7, column-purified nucleic acids from enzyme mix (enzyme) of the Kit I; lanes 4 and 8, 1 μl
buffer of the Kit I plus 4 μl DW (buffer). (D) One-step RT-PCR for the detection of MLV RNA in Platinum Taq. Nucleic acids were extracted from
50 μl of the Platinum Taq using an RNA purification column (QIAamp viral RNA mini kit [QIAGEN]) and the presence of MLV RNA was examined
by using the RT-PCR Kit P. Five μl of test samples were examined with primers indicated below the corresponding lanes. The RT-PCR condition
was the same as in Figure 1B with the exception of the PCR cycles (60 cycles instead of 45 cycles). Abbreviation; DW: distilled water. M: DNA
size marker.
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Page 4 of 7results have been inconsistent. Although all research
groups carefully performed their experiments to test
XMRV infection by PCR and/or RT-PCR, it is
still difficult to conclude that the positive results linking
XMRV with CFS are not laboratory artifacts. Xenotropic
(or polytropic) MLVs are widespread, and there may be
many opportunities for samples to get contaminated
with such ubiquitous viruses in laboratories when con-
ducting biological or medical research [17]. In this
study, we evaluated several one-step RT-PCR kits and a
Taq DNA polymerase for the contamination of MLV-
related genomes and found that the test kit and the Taq
DNA polymerase from Invitrogen were contaminated
with MLV-related genomes.
The findings in the present study indicate that con-
taminating nucleic acids in the test kits can potentially
produce false-positive PCR results in studies of XMRV
and other MLV-related viruses. In particular, our
results raise the possibility that the PCR products
described by Lo et al. [13] were derived from contami-
nating MLV RNA and/or DNA. It should be noted,
however, that in contrast to our data which shows
MLV contamination even in water controls, their
report demonstrated that polytropic MLV sequences
Contaminant    1:ATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGCTCCGCCACTGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGAATTTTTGCT 107
PmERV Chr 7    1:ATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGCTCCGCCACTGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGAATTTTTGCT 107
CFS type 1     1:ATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGCTCCGCCACTGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGGATTTTTGCT 107
CFS type 2     1:ATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGCTCCGCCACTGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGGATTTTTGCT 107
CFS type 3 1:ATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGCTCCGCCACTGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGGATTTTTGCT 107
419F
CFS type 3 1:ATCAGTTAACCTACCCGAGTCGGACTTTTTGGAGCTCCGCCACTGTACGTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGGATTTTTGCT 107
XMRV VP62      1:ATCAGTTAACCTACCCGAGTCGGACTTTTTGGA---------------GTGGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGAATTTTTGCT 92
*********************************...............*************************************************.*********
Contaminant  108:TTCGGTTTTACGCCGAAGCCGCGCCGCGCGTCTGATTTGTTT-GTTGTTCTTTTGTTCTTCGTTAGTTTTCTTCTGTCTTTAAGTGTTTTCGAGATCATGGGACAGA 213
PmERV Chr 7  108:TTCGGTTTTACGCCGAAGCCGCGCCGCGCGTCTGACTTGTTT-GTTGTTCTTTTGTTCTTCGTTAGTTTTCTTCTGTCTTTAAGTGTTTTCGAGATCATGGGACAGA 213
CFS type 1   108:TTCGGTTTTACGCCGAAACCGCGCTGCGCGTCTGATTTGTTTTATTGCTCTTTTGTTCTTCGTTAGTTTTTTTCTGTCTTTAAGTGTTTTCAAGATCATGGGACAGA 214
CFS type 2   108:TTCGGTTTTACGCCGAAACCGCGCTGCGCGTCTGATTTGTTTTATTGCTCTTTTGTTCTTCGTTAGTTTTTTTCTGTCTTTAAGTGTTTTCAAGATCATGGGACAGA 214
CFS type 3 108:TTCGGTTTTACGCCGAAACCGCGCTGCGCGTCTGATTTGTTTTATTGCTCTTTTGTTCTTCGTTAGTTTT-TTCTGTCTTTAAGTGTTTTCAAGATCATGGGACAGA 213
GAG-I-F
CFS type 3 108:TTCGGTTTTACGCCGAAACCGCGCTGCGCGTCTGATTTGTTTTATTGCTCTTTTGTTCTTCGTTAGTTTT TTCTGTCTTTAAGTGTTTTCAAGATCATGGGACAGA 213
XMRV VP62     93:TTCGGTTTTACGCCGAAACCGCGCCGCGCGTCTGATTTGTTTTGTTGTTCTTCTGTTCTTCGTTAGTTTTCTTCTGTCTTTAAGTGTTCTCGAGATCATGGGACAGA 199
*****************.******.**********.******..***.****.*****************.*****************.**.***************
Contaminant  214:CCGTAACTACCCCTCTGAGTTTAACCTTGCAGCACTGGGGAGATGTCCAGCGCATTGCATCCAACCAGTCTGTGGATGTCAGGAAGAGGCGCTGGATTACCTTCTGT 320
PmERV Chr 7  214:CCGTAACTACCCCTCTGAGTTTAACCTTGCAGCACTGGGGAGATGTCCAGCGCATTGCATCCAACCAGTCTGTGGATGTCAGGAAGAGGCGCTGGATTACCTTCTGT 320
CFS type 1   215:CCGTAACTACCCCTCTGAGTCTAACCTTGCAGCACTGGGGAGATGTCCAGCGCATTGCATCCAACCAGTCTGTGGATGTCAGGAAGGGGCGCTGGGTTACCTTCTGT 321
CFS type 2   215:CCGTAACTACCCCTCTGAGTCTAACCTTGCAGCACTGGGGAGATGTCCAGCGCATTGCATCCAACCAGTCTGTGGATGTCAGGAAGGGGCGCTGGGTTACCTTCTGT 321
CFS type 3 214:CCGTAACTACCCCTCTGAGTCTAACCTTGCAGCACTGGGGAGATGTCCAGCGCATTGCATCCAACCAGTCTGTGGATGTCAGGAAGAGGCGCTGGATTACCTTCTGT 320 CFS type 3 214:CCGTAACTACCCCTCTGAGTCTAACCTTGCAGCACTGGGGAGATGTCCAGCGCATTGCATCCAACCAGTCTGTGGATGTCAGGAAGAGGCGCTGGATTACCTTCTGT 320
XMRV VP62    200:CCGTAACTACCCCTCTGAGTCTAACCTTGCAGCACTGGGGAGATGTCCAGCGCATTGCATCCAACCAGTCTGTGGATGTCAAGAAGAGGCGCTGGGTTACCTTCTGT 306
********************.************************************************************.****.********.***********
Contaminant  321:TCCGCCGAATGGCCAACTTTCAATGTGGGATGGCCTCAGGATGGTACTTTCAATTTAAGTATTATCTCTCAGGTTAAGTCTAGAGTGTTTTGTCCTGGTCCCCACGG 427
PmERV Chr 7  321:TCCGCTGAATGGCCAACTTTCAATGTGGGATGGCCTCAGGATGGTACTTTCAATTTAAGTATTATCTCTCAGGTTAAGTCTAGAGTGTTTTGTCCTGGTCCCCACGG 427
CFS type 1   322:TCCGCCGAATGGCCAACTTTCAATGTAGGATGGCCTCAGGATGGTACTTTCAATTTAAGTATTATCCCTCAGGTTAAGTCTAGAGTGTTTTGTCATGGTCCCCACGG 428
CFS type 2   322:TCCGCCGAATGGCCAACTTTCAATGTAGGATGGCCTCAGGATGGTACTTTCAATTTAAGTATTATCCCTCAGGTTAAGTCTAGAGTGTTTTGTCATGGTCCCCACGG 428
CFS type 3 321:TCCGCCGAATGGCCAACTTTCAATGTAGGATGGCCTCAGGATGGTACTTTCAATTTAAGTATTATCTCTCAGGTTAAGTCTAGAGTGTTTTGTCCTGGTCCCCATGG 427 CFS type 3 321:TCCGCCGAATGGCCAACTTTCAATGTAGGATGGCCTCAGGATGGTACTTTCAATTTAAGTATTATCTCTCAGGTTAAGTCTAGAGTGTTTTGTCCTGGTCCCCATGG 427
XMRV VP62    307:TCCGCCGAATGGCCAACTTTCAATGTAGGATGGCCTCAGGATGGTACTTTTAATTTAGGTGTTATCTCTCAGGTCAAGTCTAGAGTGTTTTGTCCTGGTCCCCACGG 413
*****.********************.***********************.******.**.*****.*******.*******************.*********.**
Contaminant  428:ACACCCGGATCAGGTCCCATATATCGTCACCTGGGAGGCACTTGCCTATGACCCCCCTCCGTGGGTCAAACCGTTTGTGTCTCCTAAACTTCCTCCCTTGCCGACAG 534
PmERV Chr 7  428:ACACCCGGATCAGGTCCCATATATCGTCACCTGGGAGGCACTTGCCTATGACCCCCCTCCGTGGGTCAAACCGTTTGTGTCTCCTAAACTTCCTCCCTTGCCGACAG 534
CFS type 1   429:ACACCCGGATCAGGTCCCATATATCGTTACCTGGGAGGCACTTGCCTATGACCCCCCTCCGTGGGTCAAACCGTTTGTTTCTCCTAAACTTCCTCCCTTGCCGACAG 535
CFS type 2   429:ACACCCGGATCAGGTCCCATATATCGTTACCTGGGAGGCACTTGCCTATGACCCCCCTCCGTGGGTCAAACCGTTTGTTTCTCCTAAACTTCCTCCCTTGCCGACAG 535
CFS type 3 428:ACACCCGGATCAGGTCCCATATATCGTTACCTGGGAGGCACTTGCCTATGACCCCCCTCCGTGGGTCAAACCGTTTGTTTCTCCTAAACCTCCTCCCTTGCCGACAG 534 CFS type 3 428:ACACCCGGATCAGGTCCCATATATCGTTACCTGGGAGGCACTTGCCTATGACCCCCCTCCGTGGGTCAAACCGTTTGTTTCTCCTAAACCTCCTCCCTTGCCGACAG 534
XMRV VP62    414:ACACCCGGATCAGGTCCCATATATCGTCACCTGGGAGGCACTTGCCTATGACCCCCCTCCGTGGGTCAAACCGTTTGTCTCTCCTAAACCCCCTCCTTTACCGACAG 520
***************************.**************************************************.**********..*****.**.*******
Contaminant  535:CTCCCGTCCTCCCGCCCGGTCCTTCTGCGCAACCTCCGTCCCGATCTGCCCTTTACCCTGCCCTTACCCCCTCTATAAAGTCCAAACCTCCTAAGCCCCAGGTTCTC 641
PmERV Chr 7  535:CTCCCGTCCTCCCGCCCGGTCCTTCTGCGCAACCTCCGTCCCGATCTGCCCTTTACCCTGCCCTTACCCCCTCTATAAAGTCCAAACCTCCTAAGCCCCAGGTTCTC 641
CFS type 1   536:CTCCCGTCCTCCCGCCCGGTCCTTCTGCGCAACCTCCGTCCCGATCTGCCCTTTACCCTGCCCTTACCCCCTCTATAAAGTCCAAACCTCCTAAGCCCCAGGTTCTC 642
CFS type 2   536:CTCCCGTCCTCCCGCCCGGTCCTTCTGCGCAACCTCCGTCCCGATCTGCCCTTTACCCTGCCCTTACCCCCTCTATAAAGTCCAAACCTCCTAAGCCCCAGGTTCTC 642
CFS type 3 535:CTCCCGTCCTCCCGCCCGGTCCTTCTGCGCAACCTCCGTCCCGATCTGCCCTTTACCCTGCCCTTACCCCCTCTATAAAGTCCAAACCTCCTAAGCCCCAGGTTCTC 641 CFS type 3 535:CTCCCGTCCTCCCGCCCGGTCCTTCTGCGCAACCTCCGTCCCGATCTGCCCTTTACCCTGCCCTTACCCCCTCTATAAAGTCCAAACCTCCTAAGCCCCAGGTTCTC 641
XMRV VP62    521:CTCCCGTCCTCCCGCCCGGTCCTTCTGCGCAACCTCCGTCCCGATCTGCCCTTTACCCTGCCCTTACCCCCTCTATAAAGTCCAAACCTCCTAAGCCCCAGGTTCTC 627
***********************************************************************************************************
Contaminant  642:CCTGATAGCGGCGGACCTCTCATTGATCTTCTCACAGAGGACCCCCC-GCCGTACAGAGCACAACCCTCCTCCTCTGCCAGGGAGAACAATGAAGAAGAGGCGGC  745
PmERV Chr 7  642:CCTGATAGCGGCGGACCCCTCATTGACCTTCTCACAGAGGACCCCCC-GCCGTACAGAGCACAACCCTCCTCCTCTGCCAGGGAGAACGACGAAGAAGAGGCGGC  745
CFS type 1   643:CCTGATAGCGGCGGACCTCTCATTGACCTTCTCACAGAGGACCCCCC-GCCGTACGGAGCACAACCTTCCTCCTCTGCCAGGGAGAACAATGAAGAAGAGGCGGC  746
CFS type 2   643:CAGGATAGCGGCGGACCTCTCATTGACCTTCTCACAGAGGACCCCCC-GCCGTACGGAGCACAACCTTCCTCCTCTGCCAGAGAGAACAATGAAGAAGAGGCGGC  746
CFS type 3 642:CCTGATAGCGGCGGACCTCTCATTGATCTTCTCACAGAGGACCCCCCCGCCGTACGGAGCACAACCTTCCTCCTCTGCCAGGGAGAACAATGAAGAAGAGGCGGC 746
GAG-I-R
CFS type 3 642:CCTGATAGCGGCGGACCTCTCATTGATCTTCTCACAGAGGACCCCCCCGCCGTACGGAGCACAACCTTCCTCCTCTGCCAGGGAGAACAATGAAGAAGAGGCGGC 746
XMRV VP62    628:CCTGATAGCGGCGGACCTCTCATTGACCTTCTCACAGAGGATCCCCC-GCCGTACGGAGCACAACCTTCCTCCTCTGCCAGGGAGAACAATGAAGAAGAGGCGGC  731
*..**************.********.**************.*****.*******.**********.**************.******.*.************** 
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Figure 3 Sequence alignments of a partial gag region of the contaminant in Kit I with a PmERV chr 7, XMRV strain VP62, and MLV-
like sequences derived from CFS patients (CFS types 1 to 3). Origins of the sequences used for the alignment are described in the Findings.
Sequence alignments were performed using GENETYX Win ver. 6 (GENETYX, Shibuya, Tokyo, Japan).
Sato et al. Retrovirology 2010, 7:110
http://www.retrovirology.com/content/7/1/110
Page 5 of 7were found more frequently in CFS patients than in
healthy controls and not at all in water controls. None-
theless, Lo et al. mentioned in the report that Platinum
Taq from Invitrogen gave them the best results among
Taq polymerases from several suppliers and was used
to test the patient samples [13]. They also used Invi-
trogen’s Superscript II RT and Platinum Taq for RT-
PCR, albeit in a two-step cDNA synthesis and PCR
amplification procedure [13]. As pointed out by Erl-
wein et al. in the comments [19] responding to the
report by Lo et al. [13], assurance that control samples
were assayed simultaneously with the positively identi-
fied ones in a blinded, randomized way was missing in
their study, unfortunately.
The requirement for quality control to avoid contami-
nation of endogenous retroviral genomes in test kits
may differ depending on the intended purpose. How-
ever, in XMRV studies, many researchers conduct ultra-
sensitive PCR or RT-PCR to detect extremely small
amounts of XMRV. Therefore, in the investigation of
XMRV infection, researchers should prudently evaluate
test kits for the presence of genomes of endogenous
MLV as well as XMRV.
Acknowledgements
We thank Peter Gee (Institute for Virus Research, Kyoto University) for his
generous help in the preparation of this manuscript. This study was
supported by the grant-in-aids from the Blood Service Headquarters,
Japanese Red Cross Society (RAF) and Bio-oriented Technology Research
Advancement Institution (TM). Text for this section.
Author details
1Laboratory of Signal Transduction, Institute for Virus Research, Kyoto
University, 53 Shogoin-Kawaracho, Sakyo-ku, Kyoto 606-8507, Japan.
2Japanese Red Cross Osaka Blood Center, 2-4-43 Morinomiya, Joto-ku, Osaka
536-8505, Japan.
Authors’ contributions
RAF, ES, and TM designed the experiments. RAF and ES performed the
experiments. TM wrote the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Contaminant   1:ACCCGTGGGGCCCCCTAATAGTCCTGGGGATCTTAATAAGGGCAGGAGTATCAGTACAACATGACAGC 68
PmERV         1:ACCCGTGGGGCCCCCTAATAGTCCTGGGGATCTTAATAAGGGCAGGAGTATCAGTACAACATGACAGC 68
********************************************************************
Contaminant  69:CCTCATCAGGTCTTCAATGTTACTTGGAGAGTTACCAACTTAATGACAGGACAAACAGCTAATGCTAC 136
PmERV Chr 7  69:CCTCATCAGGTCTTCAATGTTACTTGGAGAGTTACCAACTTAATGACAGGACAAACAGCTAATGCTAC 136
********************************************************************
p-env1f
********************************************************************
Contaminant 137:CTCCCTCCTGGGGACAATGACCGATGCCTTTCCTAAACTGTACTTTGACTTGTGCGATTTAATAGGGG 204
PmERV Chr 7 137:CTCCCTCCTGGGGACAATGACCGATGCCTTTCCTAAACTGTACTTTGACTTGTGCGATTTAATAGGGG 204
********************************************************************
Contaminant 205:ACGACTGGGATGAGACTGGACTCGGGTGTCGCACTCCCGGGGGAAAAAAAAGGGCAAGAACATTTGAC 272
PmERV Chr 7 205:ACGACTGGGATGAGACTGGACTCGGGTGTCGCACTCCCGGGGGAAGAAAAAGGGCAAGAACATTTGAC 272
********************************************* **********************
p-env3f
*********************************************.**********************
Contaminant 273:TTCTATGTTTGCCCCGGGCATACTGTACCAACAGGGTGTGGAGGGCCGAGAGAGGGCTACTGTGGCAA 340
PmERV Chr 7 273:TTCTATGTTTGCCCCGGGCATACTGTACCAACAGGGTGTGGAGGGCCGAGAGAGGGCTACTGTGGCAA 340
********************************************************************
Contaminant 341:ATGGGGCTGTGAGACCACTGGACAGGCATACTGGAAGCCATCATCATCATGGGACCTAATTTCCCTTA 408
PmERV Chr 7 341:ATGGGGCTGTGAGACCACTGGACAGGCATACTGGAAGCCATCATCATCATGGGACCTAATTTCCCTTA 408
********************************************************************
p-env1r
********************************************************************
Contaminant 409:AGCGAGGAAACACCCCTCGGAATCAGGGCCCCTGTTATGATTCCTCAGCGGTCTCCAGTGACATCAAG 476
PmERV Chr 7 409:AGCGAGGAAACACCCCTCGGAATCAGGGCCCCTGTTATGATTCCTCAGCGGTCTCCAGTGACATCAAG 476
********************************************************************
Contaminant 476:GGCGCCACACCGGGGGGTCGATGCAATCCCCTAGTCCTAGAATTCACTGACGCAGGCAAAAAGGCCAG 544
PmERV Chr 7 476:GGCGCCACACCGGGGGGTCGATGCAATCCCCTAGTCCTGGAATTCACTGACGCGGGCAAAAAGGCCAG 544
************************************** ************** ************** ..
Contaminant 545:CTGGGATGGCCCCAAAGTATGGGGACTAAGACTGTACCGATCCACAGGGACCGACCCGGTGACCCGGT 612
PmERV Chr 7 545:CTGGGATGGCCCCAAAGTATGGGGACTAAGACTGTACCGATCCACAGGGACCGACCCGGTGACCCGGT 612
********************************************************************
Contaminant 613:TCTCTTTGACCCGCCAGGTCCTCAATATAGGGCCCCGCGTCCCCATTGGGCCTAATCCCGTG 674
PmERV Chr 7 613:TCTCTTTGACCCGCCAGGTCCTCAATATAGGGCCCCGCGTCCCCATTGGGCCTAATCCCGTG 674
**************************************************************
p-env5r
Figure 4 Sequence alignments of a partial env region of the contaminant in Kit I with a PmERV chr 7. Origins of the sequences used for
the alignment are described in the Findings. Sequence alignments were performed using GENETYX Win ver. 6 (GENETYX, Shibuya, Tokyo, Japan).
Sato et al. Retrovirology 2010, 7:110
http://www.retrovirology.com/content/7/1/110
Page 6 of 7Received: 1 November 2010 Accepted: 20 December 2010
Published: 20 December 2010
References
1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K,
Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification
of a novel Gammaretrovirus in prostate tumors of patients homozygous
for R462Q RNASEL variant. PLoS Pathog 2006, 2:e25.
2. Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D,
Derisi JL, Chow SA, Silverman RH: An infectious retrovirus susceptible to
an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci
USA 2007, 104:1655-1660.
3. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS,
Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M,
Silverman RH, Mikovits JA: Detection of an infectious retrovirus, XMRV,
in blood cells of patients with chronic fatigue syndrome. Science 2009,
326:585-589.
4. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S,
Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue
syndrome. PLoS One 2010, 5:e8519.
5. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S,
Gow JW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN: Absence of
xenotropic murine leukaemia virus-related virus in UK patients with
chronic fatigue syndrome. Retrovirology 2010, 7:10.
6. Hong P, Li J, Li Y: Failure to detect Xenotropic murine leukaemia virus-
related virus in Chinese patients with chronic fatigue syndrome. Virol J
2010, 7:224.
7. McClure M, Wessely S: Chronic fatigue syndrome and human retrovirus
XMRV. BMJ 2010, 340:c1099.
8. Switzer WM, Jia H, Hohn O, Zheng H, Tang S, Shankar A, Bannert N,
Simmons G, Hendry RM, Falkenberg VR, Reeves WC, Heneine W: Absence
of evidence of xenotropic murine leukemia virus-related virus infection
in persons with chronic fatigue syndrome and healthy controls in the
United States. Retrovirology 2010, 7:57.
9. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJ,
Swanink CM, Bleijenberg G, Netea MG, Galama JM, van der Meer JW:
Prevalence of xenotropic murine leukaemia virus-related virus in
patients with chronic fatigue syndrome in the Netherlands: retrospective
analysis of samples from an established cohort. BMJ 2010, 340:c1018.
10. Dolgin E: Chronic controversy continues over mysterious XMRV virus. Nat
Med 2010, 16:832.
11. Enserink M: Chronic fatigue syndrome. Conflicting papers on hold as
XMRV frenzy reaches new heights. Science 2010, 329:18-19.
12. Enserink M: Chronic fatigue syndrome. New XMRV paper looks good,
skeptics admit–yet doubts linger. Science 2010, 329:1000.
13. Lo SC, Pripuzova N, Li B, Komaroff AL, Hung GC, Wang R, Alter HJ:
Detection of MLV-related virus gene sequences in blood of patients
with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad
Sci USA 2010, 107:15874-15879.
14. Barnes E, Flanagan P, Brown A, Robinson N, Brown H, McClure M,
Oxenius A, Collier J, Weber J, Günthard HF, Hirschel B, Fidler S, Phillips R,
Frater J: Failure to detect xenotropic murine leukemia virus-related virus
in blood of individuals at high risk of blood-borne viral infections. J
Infect Dis 2010, 202:1482-1485.
15. Cornelissen M, Zorgdrager F, Blom P, Jurriaans S, Repping S, van
Leeuwen E, Bakker M, Berkhout B, van der Kuyl AC: Lack of detection of
XMRV in seminal plasma from HIV-1 infected men in The Netherlands.
PLoS One 2010, 5:e12040.
16. Shepherd AJ, Wilson NJ, Smith KT: Characterisation of endogenous
retrovirus in rodent cell lines used for production of biologicals.
Biologicals 2003, 31:251-260.
17. Weiss RA: A cautionary tale of virus and disease. BMC Biol 2010, 8:124.
18. Silverman RH, Nguyen C, Weight CJ, Klein EA: The human retrovirus XMRV
in prostate cancer and chronic fatigue syndrome. Nat Rev Urol 2010,
7:392-402.
19. Kaye S, Robinson M, McClure M: Chronic fatigue syndrome: xenotropic
murine leukemia virus-related virus, murine leukemia virus, both, or
neither? Proc Natl Acad Sci USA 2010, 107:E161.
doi:10.1186/1742-4690-7-110
Cite this article as: Sato et al.: An Endogenous Murine Leukemia Viral
Genome Contaminant in a Commercial RT-PCR Kit is Amplified Using
Standard Primers for XMRV. Retrovirology 2010 7:110.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sato et al. Retrovirology 2010, 7:110
http://www.retrovirology.com/content/7/1/110
Page 7 of 7